phosphatidylcholine CR (LT‑02) / Lipid Therap, Nestle, Dr Falk - LARVOL DELTA

Modified-release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-blind, Randomized, Placebo-controlled Trials. (PubMed, Clin Gastroenterol Hepatol) - P3 | "Despite prior evidence of beneficial effects of PC in phase 2 trials, our induction study with LT-02 in patients with mild to moderate UC was terminated prematurely for futility. Signals of efficacy in maintenance therapy require confirmation in an adequately-powered maintenance trial. LT-02 was safe and well tolerated."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Follow-up study with retarded release phosphatidylcholine in ulcerative colitis (clinicaltrials.gov) - Obs, N=132; No longer recruiting → Completed

Trial completion • Inflammatory Bowel Disease

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) (clinicaltrials.gov) - P3; N=150; Completed; Sponsor: Dr. Falk Pharma GmbH; Active, not recruiting ➔ Completed

Clinical • Trial completion